Shoulder Abduction Brace Against Normal Sling After Arthroscopical Rotator Cuff Suture.

Sponsor
Christian Candrian (Other)
Overall Status
Recruiting
CT.gov ID
NCT03445494
Collaborator
Clinical Trial Unit Ente Ospedaliero Cantonale (Other)
110
1
2
71.7
1.5

Study Details

Study Description

Brief Summary

The patient undergoes arthroscopic surgery to treat rotator cuff injury. At the end of the surgery, the patient will be randomized into group A (brace) or group B (normal sling).

Both groups will be also treated according to standard of care with physiotherapy and progressive introduction of movements.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Brace
  • Procedure: Normal sling
N/A

Detailed Description

The patient undergoes arthroscopic surgery to treat rotator cuff injury. At the end of the surgery, the patient will be randomized into group A (brace) or group B (normal sling).

Both groups will then perform only passive movements according to pain for the first 6 weeks supported by the physiotherapy, according to standard therapy. The following six weeks passive movements will be associated with active movements . No brace nor normal sling will be used anymore.

Patients are in study for 6 months. During this period quality of life and pain questionnaires are submitted to the patients and a MRI will be done at the end of the study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
110 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
randomized 1:1randomized 1:1
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Shoulder Abduction Brace Against Normal Sling After Arthroscopical Rotator Cuff Suture: a Randomized Monocentric Study
Actual Study Start Date :
Jan 10, 2018
Anticipated Primary Completion Date :
Jan 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Brace

After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night

Procedure: Brace
A brace to be weared according to protocol

Experimental: Normal sling

After surgery the patient must wear the normal sling for two weeks

Procedure: Normal sling
A normal sling to be weared according to protocol

Outcome Measures

Primary Outcome Measures

  1. Efficacy in the rehabilitative therapy [6 months]

    The primary objective of the study is to evaluate two different rehabilitative therapies. Efficacy is measured with a pre and post MRI

Secondary Outcome Measures

  1. Quality of life assessment [6 months]

    Evaluation of the quality of live in both groups through Constant Quality of Life questionnair up to 6 months

  2. re-rupture rate of the supraspinatus tendon [6 months]

    Evaluation of the re-rupture of the supraspinatus tendon though a follow up MRI at 6 months

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 72 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Males or females between 18 and 65 years old;

  • Presence of an isolated lesion of supraspinatus that can be documented with the MRI and which can be treated surgically by arthroscopy;

  • Presence of a supraspinatus lesion according to the Patte criteria with stage 1, 2 or 3 frontal plane ;

  • Presence of adipose degeneration ≤ 2 according to Goutallier;

  • Written informed consent to participate in the study

Exclusion Criteria:
  • Presence of a lesion of other rotator cuff tendons;

  • Previous surgical procedures of the shoulder;

  • Presence of a massive lesion, therefore irreparable, of the cuff detected intra-operatively and not observed during preoperative MRI;

  • Presence of relapsing shoulder dislocations;

  • Presence of lesions of the glenoidine cercine that require intervention;

  • Difficulties to follow the rehabilitation programs;

  • Presence of neoplastic diseases, metabolic diseases, inflammatory and systemic diseases, autoimmune diseases and immunosuppressed patients;

  • State of pregnancy (presumed or established) or breastfeeding.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ente Ospedaliero Cantonale Lugano Switzerland 6900

Sponsors and Collaborators

  • Christian Candrian
  • Clinical Trial Unit Ente Ospedaliero Cantonale

Investigators

  • Study Director: Christian Candrian, MD, EOC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christian Candrian, Deputy Head of Surgery and Orthopedy, Ente Ospedaliero Cantonale, Bellinzona
ClinicalTrials.gov Identifier:
NCT03445494
Other Study ID Numbers:
  • ORL-ORT-002
First Posted:
Feb 26, 2018
Last Update Posted:
Feb 10, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Feb 10, 2022